Compare Cytokinetics Inc (CYTK) vs Expedia Group Inc (EXPE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Expedia Group Inc — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Expedia Group Inc trades at $269.5 (market cap $32.42B). The key difference: Expedia Group Inc is far larger — about 3.8× Cytokinetics Inc's market cap, and Expedia Group Inc pays a 0.71% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Expedia Group Inc for 48 Days on average.
| CYTK | EXPE | |
|---|---|---|
Market Cap | $8.62B | $32.42B |
Volume | 2,594,626 | 1,940,671 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $339.13 |
52-Week Low | $54.76 | $188.51 |
Typical Hold Time | 19 Days | 48 Days |
Enterprise Value | $8.72B | $30.98B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Expedia Group (EXPE) trades at $258.86, down 0.38% on the day, with technical indicators showing bearish momentum as the stock tests key support levels. Fundamentally, the company demonstrates strong revenue growth from $14.73B in 2025 to projected $15.7B in 2026, with net income margins improving to 12.97%. Recent earnings beats and a 47.37% analyst buy rating support the positive outlook, though competition from AI travel agents presents headwinds.
The stock offers significant upside to the $335.06 consensus price target, representing 29% potential appreciation. Strong cash flow generation and improving profitability metrics support the bullish case, but investors must monitor competitive threats from AI disruption and recent layoffs indicating operational challenges. The current valuation at 16.28 P/E appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →
